On May 3, 1995, the U.S. Food & Drug Administration (FDA) announced it had approved Genentech’s drug CellCept (mycophenolate mofetil) for the prevention of transplant graft failure.

CellCept (mycophenolate mofetil) is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.